Who are Abridge's decision-makers?
Abridge is led by Dr. Shivdev Rao, Co-founder and CEO, with a leadership bench spanning product, science, operations, and commercialization.
- CEO
- Dr. Shivdev Rao
- Key exec
- Andy Weissman
- Founded
- 2018
- Employees
- 500+ reported in 2025
- HQ
- Pittsburgh, Pennsylvania
- Notable
- Cardiologist and former UPMC executive leading product and clinical strategy.
- Dr. Shivdev RaoCo-founder and CEOCo-founder · since 2018Cardiologist and former UPMC executive leading product and clinical strategy.
- Andy WeissmanCo-founderCo-founder · since 2018Union Square Ventures partner and early company builder.
- Tina Shah, MDChief Clinical OfficerExecutivePulmonologist focused on clinician workflow and deployment quality.
- Zachary LiptonChief Scientific OfficerExecutiveML researcher advising clinical AI model development.
Who leads Abridge?
Dr. Shivdev Rao serves as Co-founder and CEO; Andy Weissman serves as Co-founder; Tina Shah, MD serves as Chief Clinical Officer; Zachary Lipton serves as Chief Scientific Officer. The leadership pattern reflects the company's focus on clinical ambient ai.
For outreach, leadership background matters because it shows whether decisions are likely to be product-led, science-led, clinical, industrial, or government-procurement heavy.
Who actually makes buying decisions at Abridge?
Likely buying committees include the executive owner of Ambient clinical documentation, security and compliance leaders, finance/procurement, and the technical leaders responsible for integration.
A seller should avoid starting with a generic CEO pitch unless the offer is strategic. Most practical deals will need a functional champion who owns deployment pain and a finance or operations approver.
How is Abridge organized as it scales?
Abridge's public footprint suggests a scaling private company with cross-functional teams around product, engineering, customer deployment, and go-to-market or R&D. Exact reporting lines are not public.
The safest assumption is a matrixed buying process: technical validation first, operational proof second, and executive approval for larger commitments.
As of June 2026.Sources:Abridge websiteAbridge careers/about
Abridge — frequently asked questions
